Johnson & Johnson EBIT

The latest EBIT for JNJ is $26B as of June 2026. That compares with $30B in the prior-year period — down 14.6% year over year. That is above the Healthcare sector average of $23B. Investors often review this figure alongside Johnson & Johnson's historical trend and sector peers before judging valuation or financial health.

Over the past year, JNJ's EBIT moved from $30B to $26B — a 14.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Johnson & Johnson's operating scale or balance-sheet position.

Against Healthcare companies, JNJ currently prints $26B for EBIT, while the sector average sits near $23B. That is roughly 9.5% above the sector mean. Large gaps often invite a closer look at Johnson & Johnson's growth, margins, and balance sheet.

A EBIT figure of $26B for JNJ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting JNJ's EBIT ($26B), review year-over-year change from $30B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.